Danish pharmaceutical heavyweight Novo Nordisk, the company behind the blockbuster diabetes and weight-loss drug Ozempic, has announced a strategic partnership with US artificial intelligence firm Anthropic. The collaboration will see the drugmaker integrate Anthropic's Claude models, including the newly launched Claude Science, into its research and development (R&D) pipeline to accelerate the discovery of new medicines.
In a statement released on Wednesday, Mike Doustdar, president and CEO of Novo Nordisk, said the partnership would "supercharge" the company's R&D organisation and help it deliver "transformative health solutions" for people living with chronic diseases. The move underscores a broader industry trend of pharmaceutical companies turning to AI to compress the lengthy and costly process of bringing new drugs to market.
Beyond boosting productivity, Doustdar highlighted that AI tools could unlock "completely new scientific opportunities," particularly in reasoning about human biology and the mechanisms of drug action. This is not just about doing the same work faster, but about asking new questions and exploring avenues that were previously out of reach.
Anthropic's co-founder and CEO, Dario Amodei, framed the partnership in ambitious terms. "AI's increasing capability brings with it the potential to compress a century's worth of biological and medical breakthroughs into a decade," he said. By giving leading researchers access to "safe, capable, and trusted frontier models," Amodei argued that research timelines could be shortened, outcomes improved, and medicines discovered that significantly enhance human life.
The deal is the latest in a series of AI investments by the Danish company. In April, Novo Nordisk struck a separate agreement with OpenAI to use its science-focused GPT-Rosalind model for analysing complex datasets, identifying potential drug candidates, and reducing the time between initial research and patient access. The company is clearly betting that a portfolio of AI partnerships will give it an edge in the highly competitive pharmaceutical sector.
Anthropic's technology has already been the subject of scrutiny and interest across Europe. The company has previously revealed that it blocked attempts to misuse its AI for cyberattacks and bioweapons research, a reminder of the dual-use nature of such powerful tools. Meanwhile, European institutions are grappling with how to regulate and harness AI, with the EU's cybersecurity agency finally gaining access to Anthropic's Mythos 5 model, as reported earlier.
A Nordic AI hub takes shape
The partnership also builds on Denmark's broader ambitions to become a European hub for AI-driven science. In 2024, the Novo Nordisk Foundation, together with Nvidia and the Export and Investment Fund of Denmark (EIFO), established the Danish Centre for AI Innovation. The centre operates Gefion, Denmark's first AI-ready supercomputer, which is already being used for research in areas ranging from drug discovery to climate modelling.
For Copenhagen, the collaboration between Novo Nordisk and Anthropic is a signal that Danish life sciences are at the forefront of the AI revolution. It also raises questions about the concentration of such powerful technology in the hands of a few global players, and the need for European oversight. As AI becomes more integrated into critical sectors like healthcare, the balance between innovation and safety will remain a key theme for policymakers in Brussels and national capitals.
For now, the focus is on the potential. Novo Nordisk's move is a clear bet that AI can transform the economics of drug development, where failure rates are high and timelines stretch over a decade. If successful, the partnership could not only benefit the company's bottom line but also bring new treatments to patients faster.
